Author flags CRMD as a buy-and-hold value play citing a trailing PE of 3, a 2026 Phase 3 readout, and a potential entry near $5.60.
CRMD — LONG The author calls CorMedix a buy-and-hold value play, citing a trailing PE of 3 and a Phase 3 readout for an additional indication due late 2026. He notes a big gap down on a flat 2026 revenue forecast and suggests a potential entry at $5.60 or less while support sits near $7 with moving averages trending down. He explicitly says buy at your own risk.
CRMD Put it on your watchlist, big gap down on flat revenue forecast for 2026, has Phase 3 readout for additional indication due late 2026, TRAILING PE OF 3, I see value in this one buy and hold play!
This Reddit post, published January 14, 2026, features u/12HAMMER-U discussing CRMD. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/12HAMMER-U · Tickers: CRMD